Plain-English translation of NCT05410275 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing , a blood-thinning medication, in people who receive chronic dialysis for kidney failure. The study will test three different doses of the medication to understand how the body processes it and which dose works best for dialysis patients. This information will help doctors decide how to safely treat dialysis patients who need blood thinners in the future.
Dialysis patients have unique challenges with their kidneys' ability to clear medications from their bodies, which can make standard blood thinner doses unsafe. This medication hasn't been properly studied in this specific population, so researchers need to figure out the right dose that provides protection without causing bleeding complications.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth for three days, then have a four-day break, then take a different dose for three days, repeating this pattern three times with three different doses. The study team will monitor how your body processes the medication through blood tests and assessments of how well it works. The entire study takes about three weeks of active medication use plus observation periods.
AI-generated summary from trial data · Jul 2, 2026 · Not medical advice
France